Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Asceneuron SA logo — Targeting the root cause of neurodegeneration

Asceneuron SA

Targeting the root cause of neurodegeneration

Founded 2012 Switzerland Lausanne, Switzerland 20 employees Series C Total: $130.00M Biotechnology, Health Care +1

General Information

Company Name Asceneuron SA
Founded Year 2012
Location Switzerland Lausanne, Switzerland +1
Founders / Decision Makers
Team member
Employees 20
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series C
Social

Get notified when Asceneuron SA moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Asceneuron SA

Asceneuron SA is a Switzerland-based clinical stage biotech company with a focus on developing orally bioavailable therapeutics for neurodegenerative disorders. With the mission of targeting the root cause of neurodegeneration, Asceneuron's pipeline aims to address a wide range of neurodegenerative diseases such as orphan tauopathies, Alzheimer’s, and Parkinson’s disease. The company has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson’s disease and Alzheimer’s. Established in 2012, Asceneuron has garnered significant support from a renowned syndicate of investors including Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and Kurma Partners. Their most recent Series C investment of $100.00M on 16 July 2024 saw participation from a diverse group of investors including Novo Holdings, OrbiMed, GlaxoSmithKline, MERL Ventures Fund, EQT Life Sciences, and Johnson & Johnson Innovation – JJDC, reflecting industry confidence in the company's potential. Asceneuron's dedication to addressing the significant unmet medical needs in neurodegenerative disorders and the strong backing from prominent investors position it as a notable player in the biotechnology and health care sectors. For more information, visit www.asceneuron.com.

Taxonomy: Neurodegenerative Diseases, Biotech Company, Orphan Tauopathies, Alzheimer's Disease, Parkinson's Disease, Small Molecule Therapeutics, O-GlcNAcase Inhibitors, Clinical Stage Development, Neurofibrillary Tangles, Frontotemporal Dementia, Healthcare Innovation, Drug Discovery, Investment Syndicate, Neurological Disorders, Therapeutic Development

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series C •••••• 8
Investor Investor Investor Investor Investor Investor
•••• •••• 		16 Jul 2024
Grant •••••• 1
Investor
04 May 2022
Grant •••••• 1
Investor
06 Oct 2016
Series A •••••• - 29 Sep 2015

Asceneuron SA Alternatives & Competitors

Asceneuron SA vs
CuraSen Therapeutics, Inc.
CuraSen Therapeutics, Inc. United States

Targeting neurodegeneration with novel science and treatments so patients can THINK, AGAIN

Grant
20 employees
Biotechnology, Health and Wellness
Asceneuron SA vs
Annovis Bio, Inc.
Annovis Bio, Inc. United States

Transforming how we treat Alzheimer’s, Parkinson’s, and beyond.

IPO
12 employees
Biotechnology, Health and Wellness
Asceneuron SA vs
ProMIS™ Neurosciences, Inc.
ProMIS™ Neurosciences, Inc. United States

Precision therapeutics for protein misfolding disorders, including Alzheimer's, ALS and Parkinson’s...

Unknown
22 employees
Biotechnology, Health Care

FAQ About Asceneuron SA

Targeting the root cause of neurodegeneration
Asceneuron SA was founded in 2012.
Asceneuron SA is headquartered in Lausanne, Switzerland.
Asceneuron SA operates in the following industries: Biotechnology, Health Care, Health and Wellness.
Asceneuron SA has approximately 20 employees.
Asceneuron SA has completed 4 funding rounds, raising a total of $130.00M. The latest funding stage is Series C.
Top alternatives and competitors to Asceneuron SA include CuraSen Therapeutics, Inc., Annovis Bio, Inc., ProMIS™ Neurosciences, Inc., Selonterra, Inc., Neuraly Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Asceneuron SA and CuraSen Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Asceneuron SA and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy